Price T Rowe Associates Inc Apellis Pharmaceuticals, Inc. Transaction History

Price T Rowe Associates Inc

  • $883 Billion
  • Q2 2025

A detailed history of Price T Rowe Associates Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 92,151 shares of APLS stock, worth $2.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
92,151
Previous 90,700 1.6%
Holding current value
$2.2 Million
Previous $1.98 Million 19.56%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
BUY
$16.36 - $23.0 $23,738 - $33,373
1,451 Added 1.6%
92,151 $1.6 Million
Q1 2025

May 14, 2025
SELL
$21.87 - $34.63 $5.86 Million - $9.28 Million
-267,878 Reduced 74.71%
90,700 $1.98 Million
Q4 2024

Feb 14, 2025
SELL
$26.18 - $35.42 $520,406 - $704,078
-19,878 Reduced 5.25%
358,578 $11.4 Million
Q3 2024

Nov 14, 2024
SELL
$28.84 - $41.15 $25.9 Million - $37 Million
-897,970 Reduced 70.35%
378,456 $10.9 Million
Q2 2024

Aug 14, 2024
SELL
$38.07 - $59.71 $45 Million - $70.6 Million
-1,182,820 Reduced 48.1%
1,276,426 $49 Million
Q1 2024

May 15, 2024
SELL
$55.39 - $72.47 $60,541 - $79,209
-1,093 Reduced 0.04%
2,459,246 $145 Million
Q4 2023

Feb 14, 2024
BUY
$37.14 - $64.82 $25.1 Million - $43.9 Million
677,098 Added 37.97%
2,460,339 $147 Million
Q3 2023

Nov 14, 2023
SELL
$23.65 - $89.22 $125 Million - $472 Million
-5,288,985 Reduced 74.79%
1,783,241 $67.8 Million
Q2 2023

Aug 14, 2023
BUY
$76.68 - $93.31 $190 Million - $232 Million
2,482,186 Added 54.08%
7,072,226 $644 Million
Q1 2023

May 15, 2023
BUY
$46.59 - $66.96 $85.7 Million - $123 Million
1,840,498 Added 66.94%
4,590,040 $303 Million
Q4 2022

Feb 14, 2023
SELL
$43.24 - $61.04 $26 Million - $36.7 Million
-601,421 Reduced 17.95%
2,749,542 $142 Million
Q3 2022

Nov 14, 2022
SELL
$44.76 - $69.66 $239 Million - $371 Million
-5,328,850 Reduced 61.39%
3,350,963 $229 Million
Q2 2022

Aug 15, 2022
BUY
$35.07 - $59.21 $27.9 Million - $47.1 Million
794,974 Added 10.08%
8,679,813 $393 Million
Q1 2022

May 16, 2022
BUY
$35.46 - $54.12 $91.7 Million - $140 Million
2,586,348 Added 48.81%
7,884,839 $401 Million
Q4 2021

Feb 14, 2022
BUY
$30.74 - $49.16 $15.1 Million - $24.2 Million
491,414 Added 10.22%
5,298,491 $251 Million
Q3 2021

Nov 15, 2021
SELL
$31.4 - $69.84 $11.4 Million - $25.4 Million
-363,417 Reduced 7.03%
4,807,077 $158 Million
Q2 2021

Aug 16, 2021
BUY
$40.9 - $64.9 $62.5 Million - $99.2 Million
1,528,345 Added 41.96%
5,170,494 $327 Million
Q1 2021

May 17, 2021
BUY
$40.8 - $57.39 $24.4 Million - $34.3 Million
596,820 Added 19.6%
3,642,149 $156 Million
Q4 2020

Feb 16, 2021
BUY
$30.79 - $57.2 $93.8 Million - $174 Million
3,045,329 New
3,045,329 $174 Million

Others Institutions Holding APLS

# of Institutions
295
Shares Held
132M
Call Options Held
2.97M
Put Options Held
623K
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.63B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email